Altaris to Buy Simulations Plus in $375M Deal
Private equity firm Altaris has agreed to acquire pharmaceutical software maker Simulations Plus for $375 million.
Private equity firm Altaris has struck a $375 million deal to acquire Simulations Plus, a software company specializing in simulation and modeling tools for the pharmaceutical and biotechnology industries. The agreement marks a significant consolidation move in the growing market for drug-development technology platforms.
Simulations Plus provides software used by researchers and scientists to model drug behavior, helping companies reduce the time and cost associated with bringing new treatments to market. Its tools are considered essential in the early stages of pharmaceutical development, where predictive modeling can determine whether a compound is worth advancing through costly clinical trials.
Read more Tata Electronics Clears Pollution Probe at Apple iPhone Parts Plant →
For Altaris, a healthcare-focused private equity firm, the acquisition represents a strategic bet on the increasing role of computational tools in drug discovery. As biopharma companies face mounting pressure to accelerate pipelines while managing expenses, demand for simulation-driven platforms has grown steadily, making Simulations Plus an attractive target in the sector.
The deal underscores a broader trend of private equity activity in health-tech and pharmaceutical software, where recurring revenue models and deep industry integration make targets particularly appealing to long-term investors. A transaction of this scale signals continued investor confidence in the infrastructure supporting drug development.
Continue reading at SeekingAlpha.
